




Constraints in access to cystic fibrosis treatment and diagnosis vary dramatically in the region with the difference between the highest and the lowest-scoring country of about 35 points. The main reasons for moderate V4 performance is low share of patients on triple combination CF therapy in all countries but Czechia.

POPULATION BURDEN



DALY* - RATE PER 100K



Estimated values. There is no data for the EU and Western Europe average.

*disability adjusted life-years

CROSS-COUNTRY




COMPLIANCE WITH GUIDELINES

Clinical practice guidelines recommend the use of 3 cystic fibrosis drugs. Overall, at least 2 of them are available in V4 countries - compliance with the guidelines is assessed at 67%–100%.




TARGET POPULATION

KAFTRIO




DRUG ACCESS


NUMBER OF PATIENTS TREATED (2021)



POPULATION TREATED (%)



FROM REGISTRATION TO REIMBURSEMENT



LEGEND

Authorization date



Date of regular reimbursement

1162

Number of days



MAIN ISSUES

- The average time to reimbursement for cystic fibrosis drugs in the V4 countries is 5.2 years. The difference between the shortest and the longest mean time to reimbursement between the countries is 0.6 years.
- Financing of the triple combination CF therapy either in regular reimbursement and early access programmes was implemented in V4 states in 2021 in all V4 countries but Poland with very different results from less than 10% of target population treated in Hungary to 83% of target population treated in Czechia. Reimbursement of triple combination therapy in Poland was launched in 2022 and thus the 2021 score is 0%.



G.A.P. PROJECT

We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).

FIND OUT MORE AT GAPV4.EU

